NeurogesX Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: San Carlos CA United States (1998)
Status: Defunct (2013)

Organization Overview

First Clinical Trial
2002
NCT00034710
First Marketed Drug
2009
capsaicin (qutenza)
First NDA Approval
2009
capsaicin (qutenza)
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

Neurogesx

Active Ingredients

Marketed Drugs (1)

capsaicin (qutenza) (2009 NDA)

Drugs in Phase 3 Trials (1)

capsaicin (qutenza) (17 trials)

Drugs in Phase 2 Trials (2)

lidocaine (xylocaine) (1 trial)

prilocaine (citanest) (1 trial)

Indications

Approved Indications


 

Arthritis

Back Pain

Bursitis

Muscle Cramp

Myalgia

Neuralgia

Neuralgia, Postherpetic

Osteoarthritis

Pain

Tendinopathy

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetic Neuropathies (Phase 2)

Herpes Zoster (Phase 3)

HIV Infections (Phase 3)

Nervous System Diseases (Phase 3)

Neuralgia (Phase 3)

Neuralgia, Postherpetic (Phase 3)

Pain (Phase 2)

Peripheral Nervous System Diseases (Phase 3)

Polyneuropathies (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 3